(New York, USA) DelveInsight’s “Graft versus host disease Pipeline Insight – 2023” report provides comprehensive global coverage of available, marketed, and pipeline GVHD therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Graft versus host disease pipeline domain.
Request for sample report @ Graft versus host disease Pipeline Report
Key Takeaways from the Graft versus host disease Pipeline Report
- DelveInsight’s Graft versus host disease pipeline report depicts a robust space with 60+ active players working to develop 60+ pipeline therapies for Graft versus host disease treatment.
- Key Graft versus host disease companies such as Biocon, medac GmbH, MaaT Pharma, ElsaLys Biotech, Glia, Syndax Pharmaceuticals, ASC Therapeutics, SCM Lifescience, REGiMMUNE, Roche, VectivBio, Chia Tai Tianqing Pharmaceutical Group, Amgen, Pfizer, Plexxikon, Medsenic, Xenothera, and others are evaluating new drugs for GVHD to improve the treatment landscape.
- Promising Graft versus host disease pipeline therapies in various stages of development include ASC930, Teplizumab, MaaT013, Itolizumab, T-Guard, Axatilimab, TQ 05105, and others.
Request a sample and discover the recent advances in GVHD treatment drugs @ Graft versus host disease Pipeline Report
The Graft versus host disease pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Graft versus host disease drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the GVHD clinical trial landscape.
Graft versus host disease Overview
Graft-versus-host disease (GvHD) is a systemic disorder that occurs when the graft’s immune cells recognize the host as foreign and attack the recipient’s body cells. “Graft” refers to transplanted, or donated tissue, and “host” refers to the tissues of the recipient. It is a common complication after allogeneic hematopoietic stem cell transplant (HCT).
Find out more about Graft versus host disease treatment drugs @ Drugs for Graft versus host disease Treatment
Graft versus host disease Pipeline Drugs mentioned in the report:
|
GvHD Drugs |
Company |
Phase |
MoA |
RoA |
|
Itolizumab |
Biocon |
Phase III |
CD6 antigen inhibitors |
Intravenous |
|
T-Guard |
Xenikos |
Phase III |
T lymphocyte inhibitors; Protein synthesis inhibitors |
Intravenous |
|
MaaT013 |
MaaT Pharma |
Phase III |
Bacteria replacements; Gastrointestinal microbiome modulators |
Rectal |
|
Axatilimab |
Syndax Pharmaceuticals |
Phase II |
Macrophage colony stimulating factor receptor antagonists |
Intravenous |
|
TQ 05105 |
Chia Tai Tianqing Pharmaceutical Group |
Phase I/II |
Janus kinase-2 inhibitors |
Oral |
Learn more about the emerging Graft versus host disease pipeline therapies @ Graft versus host disease Clinical Trials
Graft versus host disease Therapeutics Assessment
The Graft versus host disease pipeline report proffers an integral view of GVHD emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Scope of the Graft versus host disease Pipeline Report
- Coverage: Global
- GVHD Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
- GVHD Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Graft versus host disease Therapeutics Assessment By Route of Administration: Intravenous, Oral, Rectal.
- Key GVHD Companies: Biocon, medac GmbH, MaaT Pharma, ElsaLys Biotech, Glia, Syndax Pharmaceuticals, ASC Therapeutics, SCM Lifescience, REGiMMUNE, Roche, VectivBio, Chia Tai Tianqing Pharmaceutical Group, Amgen, Pfizer, Plexxikon, Medsenic, Xenothera, and others
- Key GVHD Pipeline Therapies: ASC930, Teplizumab, MaaT013, Itolizumab, T-Guard, Axatilimab, TQ 05105, and others.
Dive deep into rich insights for new drugs for GVHD treatment; visit @ Graft versus host disease Medications
Table of Contents
Introduction
Executive Summary
Graft versus host disease (GVHD): Overview
What is Graft versus host disease (GVHD)?
Types of Graft versus host disease (GVHD)
Causes
Epidemiology and Risk Factors
Disease Management
GVHD Pipeline Therapeutics
Comparative Analysis
Graft versus host disease Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Graft versus host disease (GVHD)– DelveInsight’s Analytical Perspective
Late Stage Products (Preregistration)
Comparative Analysis
Itolizumab: Biocon
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
ASC930: ASC Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
TQ 05105: Chia Tai Tianqing Pharmaceutical Group
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Graft versus host disease (GVHD) Key Companies
Graft versus host disease (GVHD) Key Products
Graft versus host disease (GVHD) Unmet Needs
Graft versus host disease (GVHD) Market Drivers and Barriers
Graft versus host disease (GVHD) Future Perspectives and Conclusion
Graft versus host disease (GVHD) Analyst Views
Appendix
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting-services